Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
Lazerwith SE
62T278S1MX
Solubility: DMSO: 5 mg/mL(13
wild-type HCT116 cells are resistant to 10 μM 1-NM-PP1
24-48 hours) inhibits LnCAP and MCF7 cells viability in a dose-dependent manner
Tofogliflozin hydrate Catalog No.:M10025-2 Lazerwith SETofogliflozin, also known as CSG 452, is a potent and high selective SGLT2 inhibitor under development the treatment of diabetes mellitus. Tofogliflozin improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Tofogliflozin dose dependently suppressed glucose entry into tubular cells. High glucose exposure (30 mM) for 4 and 24 h significantly increased oxidative stress generation in tubular cells, which were
US$ 45.00
US$ 139.95
US$ 2840.11
US$ 199.00
US$ 266.66
US$ 825.90
US$ 134.56
US$ 119.00
US$ 69.95